"Thiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms.
| Descriptor ID |
D013844
|
| MeSH Number(s) |
D02.886.675 D03.383.129.708
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiazoles".
This graph shows the total number of publications written about "Thiazoles" by people in this website by year, and whether "Thiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 4 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 1 | 4 |
| 2017 | 24 | 24 | 48 |
| 2018 | 24 | 14 | 38 |
| 2019 | 10 | 6 | 16 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Thiazoles" by people in Profiles.
-
Immune thrombocytopenia: options and new perspectives. Blood Coagul Fibrinolysis. 2021 Oct 01; 32(7):427-433.
-
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIß) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses. ChemMedChem. 2021 12 06; 16(23):3548-3552.
-
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients. Expert Rev Clin Pharmacol. 2021 Oct; 14(10):1289-1294.
-
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.
-
In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease. ChemMedChem. 2021 08 05; 16(15):2339-2344.
-
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021 07; 58(1).
-
Available drugs and supplements for rapid deployment for treatment of COVID-19. J Mol Cell Biol. 2021 07 06; 13(3):232-236.
-
Role of nitazoxanide as a repurposed drug in the treatment and management of various diseases. Drugs Today (Barc). 2021 Jul; 57(7):455-473.
-
Interventions in an Ambulatory Setting to Prevent Progression to Severe Disease in Patients With COVID-19: A Systematic Review. Ann Pharmacother. 2022 03; 56(3):309-318.
-
NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther. 2022 01; 20(1):17-21.